Findings showed meloxicam/rizatriptan statistically significantly improved migraine treatment response compared with prior oral CGRP inhibitor treatment. Topline data were announced from a phase 3 ...

Calcitonin gene-related peptide (CGRP) inhibitors -- a group of drugs commonly used to treat migraine -- were associated with decreased rates of acne and rosacea compared with drugs that did not ...

The first three calcitonin gene-related peptide (CGRP) inhibitors approved for prevention of migraine displayed a reassuring safety profile in real-world clinical practice during the first 6 months ...

Significantly reduced rate of acne and rosacea seen in patients treated with CGRPi mAbs vs triptans, topiramate. HealthDay News — For patients experiencing migraine, direct calcitonin gene-related ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP ...

A surgeon is seen here in an undated stock photo. automation A new study shows that FDA-approved oral migraine drug atogepant is effective for relieving difficult-to-treat "medication overuse ...

Slate Medicines, a new Raleigh biotechnology company developing treatments for migraine and headache disorders, has announced ...

A new study shows that FDA-approved oral migraine drug atogepant is effective for relieving difficult-to-treat "medication overuse headaches" that are the result of using too much of other pain ...